Harrow Health's Q4 2025 inflection point, marked by $89.1M revenue and $24.0M operating income, has reversed sharply into Q2 2026 losses as SG&A surged to $53.3M (75% of revenue) and revenue fell to $70.7M, revealing negative operating leverage.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | -$0.46-157.3% vs -$0.18 | $71M+0.4% vs $70M |
Q2 2026 May 11, 2026 | -$0.74-72.1% vs -$0.43 | $44M-15.7% vs $52M |
Q2 2026 Mar 2, 2026 | $0.18-55.0% vs $0.40 | $89M-1.0% vs $90M |
Q4 2025 Nov 10, 2025 | $0.03-86.4% vs $0.22 | $72M-2.8% vs $74M |
Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, to launch HarrowRx, Harrow's new prescribing and access platform. HarrowRx gives eye care providers the ability to e-prescribe Harrow's branded ophthalmic portfolio from one destination within the electronic medical record (EMR) systems they already use, with built.
NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and access pharmacy platform that enables eyecare professionals to access Harrow's entire portfolio directly within the electronic medical record (EMR) systems they already use.
Harrow trades at a 52-week low due to management miscommunication and short-term revenue volatility, but its fundamentals remain robust. Vevye and Iheezo, Harrow's flagship drugs, both address large, underpenetrated markets and are positioned for significant growth as coverage expands and pricing stabilizes. Temporary headwinds, including inventory dynamics and coverage transitions, have obscured accelerating prescription trends and pricing tailwinds expected to materialize in H2 and beyond.
Benchmark HROW against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Harrow Health, Inc. (HROW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $26.89 | $1B | -26.98 | 36.41% | -13.51% | -104.9% | — | |
| $32.96 | $1.34B | 13.14 | 17.12% | 6.67% | 27.44% | 1.44% | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $10.08 | $548.45M | -19.57 | -3.13% | -32.13% | -51.66% | — | |
| $172.11 | $4.3B | 71.73 | -6.38% | 2.76% | 2.81% | — | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — |
Harrow Health, Inc. (HROW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Harrow Health, Inc. (HROW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Aug 6, 2026·SEC
Jun 22, 2026·SEC
Get notified when HROW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Harrow Health, Inc. (HROW) stock FAQ — growth, dividends, profitability & financials explained
Harrow Health, Inc. (HROW) reported $275.6M in revenue over the trailing twelve months. Revenue was $272.3M in fiscal year 2025.
Harrow Health, Inc. (HROW) grew revenue by 21.1% over the trailing twelve months, compared with the twelve months before.
No. Harrow Health, Inc. (HROW) reported a net loss of $37.2M over the trailing twelve months.
Harrow Health, Inc. (HROW) had a return on equity (ROE) of -104.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Harrow Health, Inc. (HROW) generated $5.7M in free cash flow over the trailing twelve months.
